Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Smoking was Associated With Poor Response to Intravenous Steroids Therapy in Graves’ Ophthalmopathy
source: The British Journal of Ophthalmology
authors: Xing L, Ye L, Zhu W, Shen L, Huang F, Jiao Q, Zhou X, Wang S, Wang W, Ning Gsummary/abstract:
Previous studies have shown that smoking is closely related to the occurrence, severity and response to orbital radiation in Graves’ ophthalmopathy (GO). The aim of this study was to investigate whether smoking impacts the response to intravenous 4.5 g methylprednisolone therapy in patients with active moderate-to-severe GO.
Ninety-two individuals with active moderate-to-severe GO who were treated with cumulative doses of 4.5 g intravenous methylprednisolone within 3 months were recruited. The patients were grouped as never smokers, active smokers (including smokers and quit smokers) and passive smokers.
We observed significantly greater response rate in never smokers compared with active smokers (73.9% vs 29.0%, p=0.001). After adjusting the confounding factors such as age, sex, body mass index, clinical activity score, thyroid-stimulating hormone receptor antibody and the duration of GO, smoking was independently associated with poor intravenous glucocorticoid (GC) response (OR 12.40, 95% CI 1.20 to 128.14, p=0.035). We also found the response rate was significantly higher in never smokers than in quit smokers (73.9% vs 16.7%, p=0.001), while no statistical significance between current smokers and quit smokers (36.8% vs 16.7%, p=0.228). There was a trend of poor response for passive smokers compared with never smokers (64.7% vs 72.2%, p=0.583).
Smoking, even past smoking, was an independent risk factor associated with impaired response to intravenous corticosteroids in patients with GO. Smokers with GO should be given optimised treatment strategy such as higher dose of GC or combined radiation therapy.
Breakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...
Efficacy of B-cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves’ Orbitopa...Background: Preliminary studies have sh...
Casey Eye Institute – Thyroid Eye Disease CenterAs part of Oregon Health & Science U...
“TED Today” Episode 3https://www.youtube.com/watch?v=NqM9kf1h...
Predictive Score for the Development or Progression of Graves’ Orbitopathy in Patients With Newly Diagnosed Gr...Objective: To construct a predictive sc...
Brian Chuck Tse, MDBrian Chuck Tse is an Assistant Professo...
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves’ OphthalmopathyThe purpose of the current study is to c...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.